Watch More Highlights
Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses agents in phase III studies (both ongoing and planned), how the treatment landscape for myelofibrosis is changing, and what advanced practitioners need to know about managing adverse events, drug mechanisms of action, and staying up to date on the pipeline.